Danish pharmaceutical giant Lundbeck, which is one of several companies fined by the European Commission after an industry-wide probe, is slamming the regulator for fining the company on what it deems unreasonable grounds. The Commission raided Lundbeck offices in 2005 and then fined the company for making anticompetitive agreements with other pharmaceutical companies that barred them from producing generic forms of ones of Lundbeck’s most popular drugs. While the company claims those agreements were legal, and that it had the right to make those contracts while key patent lawsuits were being decided, the European Commission is fighting pharmaceutical companies against such so-called pay-for-delay schemes. Lundbeck is currently speaking out against the regulator for fining the company and modifying its accusations after the company sent a statement of objections concerning the Commission’s ruling.
Full Content: European Voice
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI